BR112023025459A2 - Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos - Google Patents
Inibidores da tirosina quinase de bruton e métodos de uso dos mesmosInfo
- Publication number
- BR112023025459A2 BR112023025459A2 BR112023025459A BR112023025459A BR112023025459A2 BR 112023025459 A2 BR112023025459 A2 BR 112023025459A2 BR 112023025459 A BR112023025459 A BR 112023025459A BR 112023025459 A BR112023025459 A BR 112023025459A BR 112023025459 A2 BR112023025459 A2 BR 112023025459A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- tyrosine kinase
- kinase inhibitors
- bruton
- malignancies
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title abstract 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title abstract 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title abstract 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196843P | 2021-06-04 | 2021-06-04 | |
| PCT/IB2022/055154 WO2022254371A1 (en) | 2021-06-04 | 2022-06-02 | Inhibitors of bruton's tyrosine kinase and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023025459A2 true BR112023025459A2 (pt) | 2024-02-27 |
Family
ID=82214195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023025459A BR112023025459A2 (pt) | 2021-06-04 | 2022-06-02 | Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12622910B2 (enExample) |
| EP (1) | EP4346834A1 (enExample) |
| JP (1) | JP2024520630A (enExample) |
| KR (1) | KR20240019214A (enExample) |
| CN (1) | CN117412753A (enExample) |
| AU (1) | AU2022284369A1 (enExample) |
| BR (1) | BR112023025459A2 (enExample) |
| CA (1) | CA3220015A1 (enExample) |
| CL (2) | CL2023003564A1 (enExample) |
| IL (1) | IL308951A (enExample) |
| JO (1) | JOP20230310A1 (enExample) |
| MX (1) | MX2023014435A (enExample) |
| TW (1) | TW202317127A (enExample) |
| WO (1) | WO2022254371A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11964976B1 (en) | 2023-09-12 | 2024-04-23 | King Faisal University | Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors |
| US20250333398A1 (en) | 2024-04-30 | 2025-10-30 | Boehringer Ingelheim International Gmbh | Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228889A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228895A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228900A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Arylamide substituted indazoles and the use thereof as medicament |
| WO2025228899A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Further heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228902A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Heterocyclic acids as sting antagonists and the use thereof as medicament |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3112415A1 (de) | 1981-03-28 | 1982-10-07 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden |
| US4886646A (en) | 1988-03-23 | 1989-12-12 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Hanging drop crystal growth apparatus and method |
| US5096676A (en) | 1989-01-27 | 1992-03-17 | Mcpherson Alexander | Crystal growing apparatus |
| US5130105A (en) | 1990-10-23 | 1992-07-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Protein crystal growth tray assembly |
| US5221410A (en) | 1991-10-09 | 1993-06-22 | Schering Corporation | Crystal forming device |
| US5430150A (en) | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
| US5300478A (en) | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
| US5400741A (en) | 1993-05-21 | 1995-03-28 | Medical Foundation Of Buffalo, Inc. | Device for growing crystals |
| WO2003016338A1 (en) | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Crystal structure of the btk kinase domain |
| AU2005284796A1 (en) | 2004-09-15 | 2006-03-23 | Janssen Pharmaceutica, N.V. | Thiazolopyridine kinase inhibitors |
| US7579356B2 (en) | 2005-05-04 | 2009-08-25 | Janssen Pharmaceutica Nv | Thia-tetraazaacenaphthylene kinase inhibitors |
| US7593820B2 (en) | 2005-05-12 | 2009-09-22 | Cytopia Research Pty Ltd | Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof |
| US7605154B2 (en) | 2005-08-08 | 2009-10-20 | Janssen Pharmaceutica N.V. | Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors |
| US7427625B2 (en) | 2006-02-08 | 2008-09-23 | Janssen Pharmaceutica, N.V. | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
| EP2471789B9 (en) | 2009-08-26 | 2015-03-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| WO2011133609A2 (en) | 2010-04-19 | 2011-10-27 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of btk inhibitors |
| FR2978441A1 (fr) | 2011-07-25 | 2013-02-01 | Diverchim | Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques |
| JP2015536446A (ja) | 2012-10-11 | 2015-12-21 | ファーマサイクリックス，インク． | Ｔｅｃファミリーキナーゼ阻害剤療法のためのコンパニオン診断 |
| EP2970291B1 (en) | 2013-03-15 | 2022-05-11 | Janssen Pharmaceutica, N.V. | Processes and intermediates for preparing a medicament |
| HRP20181109T1 (hr) | 2013-12-11 | 2018-11-02 | Biogen Ma Inc. | Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji |
| WO2015127261A1 (en) | 2014-02-21 | 2015-08-27 | Pharmacyclics, Inc. | Biomarkers for predicting response of dlbcl to treatment with ibrutinib |
| BR112017001677A2 (pt) | 2014-08-01 | 2018-07-17 | Pharmacyclics Llc | biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk |
| SMT202100674T1 (it) * | 2014-08-11 | 2022-01-10 | Acerta Pharma Bv | Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2 |
| JO3794B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| WO2018103058A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| WO2018103060A1 (en) * | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| JP2023522957A (ja) | 2020-04-21 | 2023-06-01 | フラッグシップ パイオニアリング， インコーポレイテッド | 二機能性分子およびその使用方法 |
| MX2024010134A (es) | 2022-02-18 | 2024-08-27 | Janssen Pharmaceutica Nv | Sintesis de inhibidores de tirosina quinasa de bruton. |
-
2022
- 2022-06-02 MX MX2023014435A patent/MX2023014435A/es unknown
- 2022-06-02 KR KR1020247000043A patent/KR20240019214A/ko active Pending
- 2022-06-02 EP EP22733732.6A patent/EP4346834A1/en active Pending
- 2022-06-02 CA CA3220015A patent/CA3220015A1/en active Pending
- 2022-06-02 US US17/830,714 patent/US12622910B2/en active Active
- 2022-06-02 WO PCT/IB2022/055154 patent/WO2022254371A1/en not_active Ceased
- 2022-06-02 TW TW111120615A patent/TW202317127A/zh unknown
- 2022-06-02 JP JP2023574315A patent/JP2024520630A/ja active Pending
- 2022-06-02 CN CN202280039736.2A patent/CN117412753A/zh active Pending
- 2022-06-02 BR BR112023025459A patent/BR112023025459A2/pt unknown
- 2022-06-02 IL IL308951A patent/IL308951A/en unknown
- 2022-06-02 AU AU2022284369A patent/AU2022284369A1/en active Pending
-
2023
- 2023-11-29 CL CL2023003564A patent/CL2023003564A1/es unknown
- 2023-11-29 JO JOJO/P/2023/0310A patent/JOP20230310A1/ar unknown
-
2024
- 2024-09-26 CL CL2024002895A patent/CL2024002895A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022254371A1 (en) | 2022-12-08 |
| US12622910B2 (en) | 2026-05-12 |
| CL2023003564A1 (es) | 2024-06-21 |
| EP4346834A1 (en) | 2024-04-10 |
| TW202317127A (zh) | 2023-05-01 |
| IL308951A (en) | 2024-01-01 |
| US20230013755A1 (en) | 2023-01-19 |
| CN117412753A (zh) | 2024-01-16 |
| JP2024520630A (ja) | 2024-05-24 |
| JOP20230310A1 (ar) | 2023-11-29 |
| MX2023014435A (es) | 2024-03-08 |
| AU2022284369A1 (en) | 2024-01-25 |
| CA3220015A1 (en) | 2022-12-08 |
| KR20240019214A (ko) | 2024-02-14 |
| CL2024002895A1 (es) | 2025-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014435A (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso. | |
| BR112022017724A2 (pt) | Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos | |
| BR112022014058A2 (pt) | Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms) | |
| EA202092154A1 (ru) | Комбинированная терапия | |
| BR112023009531A2 (pt) | Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos | |
| BRPI0617165A2 (pt) | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos | |
| BRPI0407993B8 (pt) | compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos | |
| DK1272188T3 (da) | Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer | |
| BR0308787A (pt) | Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona | |
| UY28441A1 (es) | Derivados de quinazolina | |
| NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
| DE60118889D1 (de) | Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs | |
| MX2023002321A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| BR112022020147A2 (pt) | Compostos para tratar a doença de huntington | |
| MX2024007328A (es) | Inhibidores macrociclicos de btk. | |
| BRPI0517435A (pt) | triazóis úteis como inibidores de proteìna cinase | |
| CL2022002699A1 (es) | Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. | |
| TW200716598A (en) | Aminoquinoline and aminoquinazoline kinase modulators | |
| BRPI0411364A (pt) | compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos | |
| BR112024001989A2 (pt) | Anticorpos anti-hla-g | |
| GEAP202416348A (en) | Methods and uses for treating anhedonia | |
| BR112022024751A2 (pt) | Uso de um inibidor de fosfodiesterase 10 para o tratamento da síndrome de tourette |